Only 6 imported drugs are to be selected for the seventh batch of centralized procurement. Do multinational pharmaceutical companies choose to "lie down"?

[Pharmaceutica.
com Market Analysis] In the early years, multinational pharmaceutical companies made a lot of money easily in the Chinese pharmaceutical mark.
Now, with the advancement of medical reform policies such as centralized procurement, medical insurance negotiation, and the two-invoice system, multinational pharmaceutical companies seem to have insufficient stami.
How to maintain the rapid growth in the Chinese market has become a major issue faced by these pharmaceutical compani.
Recently, the results of the seventh batch of drug centralized procurement have been releas.
Chinese pharmaceutical companies are still the main for.
A total of 211 pharmaceutical companies and 321 products have been selected, while only 6 multinational pharmaceutical companies have 6 products to be select.
In contrast, are multinational pharmaceutical companies choosing to "lie down"? The principle of centralized procurement is to exchange quantity at a low pri.
Compared with domestic drugs, imported drugs are more difficult to control in terms of co.
Therefore, in order to ensure their own global price system, some multinational pharmaceutical companies voluntarily chose to give up in-hospital drugs during centralized procureme.
market, and then sell the original research products through the out-of-hospital mark.
For example, Huizhi's lipid-lowering drug Lipitor (atorvastatin calcium tablets), which was transferred to the out-of-hospital market after the first batch of national centralized procurement failed to win the bid, the company stated in its 2021 financial report that the growth of new channels will partly This offset the decline in sales in hospitals due to volume purchas.
However, it also admitted that the low price pressure and sales pressure will continue to exist in 2022 when selling drugs in hospitals, which may have a negative impact on the company's performan.
The 2021 financial report shows that Lipitor is still the variety that brings high sales to Huizhi, with global annual sales reaching US$663 billi.
Of course, with the normalization of centralized procurement, the attitude of multinational pharmaceutical companies has gradually changed, and a few varieties have successfully entered the list of centralized procureme.
For example, in the fifth batch of centralized procurement, 10 foreign companies won the bid for 11 products, a significant increase compared with the previous 2 to 4 bids; in the sixth batch of insulin special centralized procurement, multinational pharmaceutical companies have become the "main force" ”, Novo Nordisk, Sanofi, Eli Lilly and other three major multinational leading companies' bidding products are all planned to be selected, and the participation of foreign companies has increased significant.
And in terms of price cuts, multinational pharmaceutical companies have also shown a certain degree of "sincerit.

In the seventh batch of centralized procurement, Pfizer's tigecycline, Japan's Astellas company's Micafungin, Spain's Amerol's ebastine, Italy's Bracco Xinyi company's dipatrol, e.

4 original research drugs were selected, with an average price reduction of 6
"But for the varieties after centralized procurement, regardless of whether they win the bid or not, multinational pharmaceutical companies will still be affect.

For example, they no longer need as many people as they used .

" A person from a multinational pharmaceutical company told the med.

In general, under the centralized procurement, the entire pharmaceutical industry is undergoing chang.

Whether the products of multinational companies are successful or not, they are actually facing varying degrees of impact, and the market structure in China will also usher in new chang.

In recent years, it can be found that a large number of multinational pharmaceutical companies, including AstraZeneca, Pfizer, Roche, Huizhi Pharmaceutical, Japanese pharmaceutical companies Daiichi Sankyo, Eli Lilly, Novo Nordisk, Astellas, Sanofi, Huizhi, e.

In recent years, it has been actively adjusting its organizational structure, through measures such as divestiture and merger of business lines, replacement of senior candidates, layoffs and other measures to better adapt to changes in the Chinese pharmaceutical market environment and focus on core busine.

At present, China's pharmaceutical market is growing rapidly, and it is still an important contributor to the growth of multinational pharmaceutical compani.

According to relevant reports, China's pharmaceutical market is expected to reach US$168 billion by 2023, accounting for 30% of the global market, compared with only 11% in 201In the face of this big market cake, neither multinational pharmaceutical companies nor local pharmaceutical companies want to lose .

In recent years, the strength of Chinese innovative pharmaceutical companies has been rising, and it is expected that multinational pharmaceutical companies will face increasing pressure in the Chinese market in the futu.

, in addition to responding to the new medical reform policy, it will also face competition challenges from local pharmaceutical compani.

Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.